Literature DB >> 16555164

What would the patient choose? Subjective comparison of atypical and typical neuroleptics.

A Karow1, D Schnedler, D Naber.   

Abstract

INTRODUCTION: Among the advantages of atypical antipsychotics, the lack of motor symptoms and the improvement of negative, affective, and cognitive symptoms are of clinical relevance. The aim of this study was to compare atypical and typical neuroleptics from the patient's perspective.
METHOD: To investigate differential efficacy and side effects of neuroleptics, 61 patients with schizophrenia or schizoaffective disorder, who have received typicals for 129 (+/- 194) and atypicals for 53 (+/- 68) weeks, were assessed.
RESULTS: There is strong evidence in favor of atypical neuroleptics in the domains negative ( t = 7.7; P < 0.001), cognitive ( t = 10.2; P < 0.001), and affective ( t = 5.5; P < 0.001) symptoms. The assessment of atypicals and typicals regarding positive symptoms did not differ and may be an indication of the validity of the patient's opinion. Regarding tolerability, atypical neuroleptics again are favored because of fewer motor, sexual, and vegetative side effects ( t = 4.2; P < 0.001). DISCUSSION: This study focusing on the subjective experience of patients provides further argument in support of the superiority of atypical over typical neuroleptics. The results of this study also point to the benefits of a consumer-orientated view.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16555164     DOI: 10.1055/s-2006-931541

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  6 in total

1.  The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.

Authors:  Dieter Naber; Martin Lambert
Journal:  CNS Drugs       Date:  2009-08       Impact factor: 5.749

2.  Adolescent attitudes toward psychiatric medication: the utility of the Drug Attitude Inventory.

Authors:  Lisa Townsend; Jerry Floersch; Robert L Findling
Journal:  J Child Psychol Psychiatry       Date:  2009-07-21       Impact factor: 8.982

3.  Hippocampal shape and volume changes with antipsychotics in early stage psychotic illness.

Authors:  Daniel Mamah; Michael P Harms; Deanna Barch; Martin Styner; Jeffrey A Lieberman; Lei Wang
Journal:  Front Psychiatry       Date:  2012-11-12       Impact factor: 4.157

4.  The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup.

Authors:  Michael P Wilson; David Pepper; Glenn W Currier; Garland H Holloman; David Feifel
Journal:  West J Emerg Med       Date:  2012-02

5.  Attitude towards Antipsychotic Medications in Patients Diagnosed with Schizophrenia: A Cross-Sectional Study at Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia.

Authors:  Tilahun Kassew; Demeke Demilew; Addis Birhanu; Mesele Wonde; Biks Liyew; Shegaye Shumet
Journal:  Schizophr Res Treatment       Date:  2019-05-22

6.  Combination therapy or monotherapy for the depressed type of schizoaffective disorder.

Authors:  Lubomira Izáková; Ivan Andre; Angelos Halaris
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.